title: [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
abstract: Induced sarcoïdosis during therapy with interferon for chronic viral hepatitis C involves mainly by isolated cutaneous lesions or with lung lesions. Systemic forms are very rare. We report an observation. A 50-year-old patient developed a systemic sarcoïdosis two months after the end of treatment for hepatitis C with pegylated interferon and ribavirin with lung, joint and hepatic manifestations. After starting corticosteroid therapy, the evolution was favourable. Induced sarcoïdosis by interferon therapy is rare, treatment necessitates stopping interferon, and sometimes corticosteroid therapy.
authors.affiliation: Service de médecine interne, hôpital militaire Moulay-Ismail, BP S15, Meknès, Maroc. Electronic address: mouddenkarim@yahoo.fr.
authors.forename: M K
authors.initials: MK
authors.lastname: Moudden
authors.affiliation: Service de radiologie, hôpital militaire Moulay-Ismail, Meknès, Maroc.
authors.forename: T
authors.initials: T
authors.lastname: Ziadi
authors.affiliation: Service d'anatomopathologie, hôpital militaire Mohamed V Rabat, Meknès, Maroc.
authors.forename: A
authors.initials: A
authors.lastname: Al Bouzidi
authors.affiliation: Service de pneumologie, hôpital militaire Moulay-Ismail, Meknès, Maroc.
authors.forename: A
authors.initials: A
authors.lastname: Ouarssani
authors.affiliation: Pole médical, hôpital militaire Moulay-Ismail, Meknès, Maroc.
authors.forename: L
authors.initials: L
authors.lastname: Hadri
authors.affiliation: Service de médecine interne, hôpital militaire Moulay-Ismail, BP S15, Meknès, Maroc.
authors.forename: M
authors.initials: M
authors.lastname: El Baaj
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000009:adverse effects; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D012507:Sarcoidosis / Q000139:chemically induced*; D014057:Tomography, X-Ray Computed
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: Hepatitis C; Hépatite C; Interféron pégylé; Pegylated interferon; Sarcoidosis; Sarcoïdose